60 related articles for article (PubMed ID: 38606975)
1. Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study.
Miano TA; Hennessy S; Yang W; Dunn TG; Weisman AR; Oniyide O; Agyekum RS; Turner AP; Ittner CAG; Anderson BJ; Wilson FP; Townsend R; Reilly JP; Giannini HM; Cosgriff CV; Jones TK; Meyer NJ; Shashaty MGS
Intensive Care Med; 2022 Sep; 48(9):1144-1155. PubMed ID: 35833959
[TBL] [Abstract][Full Text] [Related]
2. Implementation of vancomycin AUC/MIC dosing vs traditional trough dosing and incidence of acute kidney injury at a rural community hospital.
McClure S; McElroy L; Gugkaeva Z
Am J Health Syst Pharm; 2024 May; 81(11):e283-e288. PubMed ID: 38253056
[TBL] [Abstract][Full Text] [Related]
3. Lack of Synergistic Nephrotoxicity in a Mouse Model of Vancomycin-Induced AKI with Piperacillin-Tazobactam Coadministration.
Rozenblat D; Placier S; Frere P; Louedec L; Sejaan L; Mesnard L; Luque Y
Kidney360; 2024 May; 5(5):753-755. PubMed ID: 38556641
[No Abstract] [Full Text] [Related]
4. Relationship between nephrotoxicity and area under the concentration-time curve of vancomycin in critically ill patients: a multicenter retrospective study.
Ishigo T; Matsumoto K; Yoshida H; Tanaka H; Ibe Y; Fujii S; Fukudo M; Fujihara H; Yamaguchi F; Ebihara F; Maruyama T; Hamada Y; Samura M; Nagumoi F; Komatsu T; Tomizawa A; Takuma A; Chiba H; Nishi Y; Enoki Y; Taguchi K; Suzuki A
Microbiol Spectr; 2024 May; ():e0373923. PubMed ID: 38775483
[TBL] [Abstract][Full Text] [Related]
5. A Multicenter, Retrospective Outcome Analysis of Vancomycin Area Under the Curve versus Trough-Based Dosing Strategies in Patients with Burn OR Inhalational Injuries (MONITOR).
Santos R; Boyd AN; Walroth TA; Hall A; King J; Ahiskali A; Walter E; Neumann N; Curry D; Hoyte B; Thomas W; Adams B; Tran N; Gleason VM; Drabick Z; DeWitt A; Suarez J; Prazak AMB; Disney KA; Hill D
J Burn Care Res; 2024 Jun; ():. PubMed ID: 38900835
[TBL] [Abstract][Full Text] [Related]
6. In complicated UTIs, cefepime-taniborbactam increased treatment success vs. meropenem at 19 to 23 d.
Granwehr B
Ann Intern Med; 2024 Jun; 177(6):JC67. PubMed ID: 38830218
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the Nephrotoxicity of Area-under-the-Curve-Based Dosing of Vancomycin with Concomitant Antipseudomonal Beta-Lactam Antibiotics: A Systematic Review and Meta-Analysis.
Chiu CY; Sarwal A
Medicina (Kaunas); 2023 Mar; 59(4):. PubMed ID: 37109649
[No Abstract] [Full Text] [Related]
8. Piperacillin-Tazobactam Plus Vancomycin-Associated Acute Kidney Injury in Adults: Can Teicoplanin or Other Antipseudomonal Beta-Lactams Be Remedies?
Aslan AT; Akova M
Healthcare (Basel); 2022 Aug; 10(8):. PubMed ID: 36011239
[TBL] [Abstract][Full Text] [Related]
9. Effect modification of dosing strategy (AUC or trough) on AKI associated with vancomycin in combination with piperacillin/tazobactam or cefepime and meropenem.
Mefford B; Wallace KL; Donaldson JC; Bissell Turpin BD; Sen P; Schadler AD; Liu LJ; Thompson Bastin ML
Antimicrob Agents Chemother; 2024 May; 68(5):e0108523. PubMed ID: 38606975
[TBL] [Abstract][Full Text] [Related]
10. Incidence of Acute Kidney Injury among Patients Treated with Piperacillin-Tazobactam or Meropenem in Combination with Vancomycin.
Rutter WC; Burgess DS
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712661
[TBL] [Abstract][Full Text] [Related]
11. Impact of combining vancomycin with piperacillin/tazobactam or with meropenem on vancomycin-induced nephrotoxicity.
Tookhi RF; Kabli NA; Huntul MA; Thabit AK
Intern Emerg Med; 2021 Jun; 16(4):975-979. PubMed ID: 33439417
[TBL] [Abstract][Full Text] [Related]
12. Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.
Rutter WC; Cox JN; Martin CA; Burgess DR; Burgess DS
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895019
[TBL] [Abstract][Full Text] [Related]
13. Comparison of teicoplanin versus vancomycin in combination with piperacillin-tazobactam or meropenem for the risk of acute kidney injury.
Aslan AT; Pashayev T; Dağ O; Akova M
Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1953-1961. PubMed ID: 33884515
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem.
Robertson AD; Li C; Hammond DA; Dickey TA
Pharmacotherapy; 2018 Dec; 38(12):1184-1193. PubMed ID: 30175410
[TBL] [Abstract][Full Text] [Related]
15. Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial.
Qian ET; Casey JD; Wright A; Wang L; Shotwell MS; Siemann JK; Dear ML; Stollings JL; Lloyd BD; Marvi TK; Seitz KP; Nelson GE; Wright PW; Siew ED; Dennis BM; Wrenn JO; Andereck JW; Han JH; Self WH; Semler MW; Rice TW;
JAMA; 2023 Oct; 330(16):1557-1567. PubMed ID: 37837651
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
